Levels of vitamin D among patients with chronic hepatitis B virus infection were extremely low and prevalent when the infection was left untreated. The low levels were, however, not associated with treatment outcomes
“To our knowledge, this is the largest analysis of vitamin D levels among patients with [chronic HBV],” Henry Lik-Yuen Chan, MD, Prince of Wales Hospital, The Chinese University of Hong Kong, and colleagues wrote. “The analysis also comprises a board global sampling from 139 sites in Europe, Asia, North America, Australia and India.”
The researchers randomly assigned 740 patients to either a dosage of tenofovir disoproxil fumarate (TDF) plus pegylated interferon alfa-2a for 48 weeks, TDF plus PEG-IFN a-2a for 16 weeks followed by TDF for 32 weeks, PEG-IFN a-2a for 48 weeks, or TDF for 120 weeks.